Gary Glick gets $27M to leap back into immuno-oncology R&D with Novartis, Atlas and Abingworth in his corner
Gary Glick didn’t specifically intend to start a new biotech after he left Lycera, where he was the founder and CSO, a little more than a year ago. To hear him tell it, he wasn’t exactly sure what the next step in his career would be. But after starting out talking to some of the partners at Atlas Venture, taking the helm of a new company almost became inevitable.
“By the end of the summer (2015), we were talking one day about various ideas,” Glick recalls. He put together some slides, picking up on some of the research that had been put into the innate immune system, a field he was intimately aware of after tackling the adaptive side of the immune system at Lycera.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.